Mainstay Medical Holdings announces outcomes from RESTORE clinical trial of ReActiv8 to treat intractable chronic low back pain: Dublin, Ireland Saturday, January 18, 2025, 18:00 ...
Bethesda, Maryland Saturday, January 18, 2025, 17:00 Hrs [IST] ...
UCB’s 320 mg/2 mL prefilled syringe and autoinjector for single-injection administration option is available now in US: Brussels, Belgium Saturday, January 18, 2025, 16:00 Hrs [ ...
Caris Life Sciences collaborates with Ontada to advance oncology research and the adoption of precision medicine: Irving, Texas Saturday, January 18, 2025, 15:00 Hrs [IST] Caris L ...
UAE health ministry approves Biomerica’s Fortel PSA Screening Test to detect an early sign of prostate cancer: Irvine, California Saturday, January 18, 2025, 14:00 Hrs [IST] Bio ...
China NMPA grants marketing authorization to IMPACT Therapeutics’ Senaparib for 1L maintenance therapy in ovarian cancer: Shanghai Saturday, January 18, 2025, 15:30 Hrs [IST] IM ...
Glenmark Life Sciences, a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas, announces its change of ...
ACT, an Indian venture philanthropy platform, has committed Rs. 8.33 crore in catalytic grants to Khushi Baby and Medoplus; social startups that are pioneering tech-first solutions to revolutionise ...
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced several ...
Signet Therapeutics (Signet), a clinical-stage biotech company leveraging organoids and AI to develop first-in-class cancer therapies, announced that the first patient has been dosed in the phase I ...
Acadia Pharmaceuticals Inc., a company is advancing breakthroughs in neuroscience to elevate life, announced that the company has submitted a Marketing Authorization Application (MAA) to the European ...
Pasithea Therapeutics Corp., a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other ...